
National Research Corporation NRC
$ 18.31
5.23%
Annual report 2025
added 03-05-2026
National Research Corporation Total Shareholders Equity 2011-2026 | NRC
Annual Total Shareholders Equity National Research Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14 M | 31.3 M | 49 M | 72 M | 85.3 M | 64.3 M | 32.9 M | 19.1 M | 90 M | 82.8 M | 74.2 M | 87.7 M | 71.8 M | 56.7 M | 55.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 90 M | 14 M | 59.1 M |
Quarterly Total Shareholders Equity National Research Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.3 M | 21.3 M | 29.7 M | 31.3 M | 34.6 M | 40.2 M | 36.9 M | 49 M | 57.9 M | 77.8 M | 74.7 M | 72 M | 67.8 M | 68.6 M | 81.5 M | 85.3 M | 83.1 M | 76.4 M | 73.2 M | 64.3 M | 64.3 M | 64.3 M | 64.3 M | 32.9 M | 32.9 M | 32.9 M | 32.9 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 90 M | 90 M | 90 M | 90 M | 82.8 M | 82.8 M | 82.8 M | 82.8 M | 74.2 M | 74.2 M | 74.2 M | 74.2 M | 87.7 M | 87.7 M | 87.7 M | 87.7 M | 71.8 M | 71.8 M | 71.8 M | 71.8 M | 56.7 M | 56.7 M | 56.7 M | 56.7 M | 55.6 M | 55.6 M | 55.6 M | 55.6 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 90 M | 14.3 M | 61.3 M |
Total Shareholders Equity of other stocks in the Diagnostics research industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
27.5 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
-48.2 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
6.73 M | - | -6.19 % | $ 10.5 M | ||
|
Bioventus
BVS
|
184 M | $ 9.0 | 1.47 % | $ 600 M | ||
|
Brainsway Ltd.
BWAY
|
19.6 M | $ 13.99 | 2.49 % | $ 99.4 M | ||
|
Castle Biosciences
CSTL
|
456 M | $ 26.24 | 1.59 % | $ 729 M | ||
|
Charles River Laboratories International
CRL
|
3.16 B | $ 154.17 | 1.45 % | $ 7.64 B | ||
|
DexCom
DXCM
|
2.75 B | $ 68.54 | 3.32 % | $ 26.7 B | ||
|
CareDx, Inc
CDNA
|
303 M | $ 17.77 | 2.6 % | $ 947 M | ||
|
Guardant Health
GH
|
-99.3 M | $ 88.16 | 1.12 % | $ 11.1 B | ||
|
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
2.4 B | $ 103.95 | 0.1 % | $ 19.6 B | ||
|
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
1.69 B | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
1.13 B | $ 15.57 | 4.15 % | $ 471 M | ||
|
Biodesix
BDSX
|
20.9 M | $ 17.22 | -0.4 % | $ 2.23 B | ||
|
ICON Public Limited Company
ICLR
|
9.52 B | $ 101.08 | 3.55 % | $ 8.34 B | ||
|
Anixa Biosciences
ANIX
|
15.2 M | $ 2.88 | 1.23 % | $ 93.5 K | ||
|
IQVIA Holdings
IQV
|
6.5 B | $ 169.85 | 3.01 % | $ 29.2 B | ||
|
Danaher Corporation
DHR
|
52.5 B | $ 195.65 | 2.23 % | $ 139 B | ||
|
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
2.37 B | $ 121.72 | 2.04 % | $ 19.4 B | ||
|
Quest Diagnostics Incorporated
DGX
|
7.17 B | $ 198.39 | -0.28 % | $ 22 B | ||
|
QIAGEN N.V.
QGEN
|
3.57 B | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
5.39 B | $ 113.9 | 1.85 % | $ 34.6 B | ||
|
BioNano Genomics
BNGO
|
35.4 M | $ 1.12 | 0.91 % | $ 1.42 M | ||
|
DarioHealth Corp.
DRIO
|
58.1 M | $ 9.28 | 10.24 % | $ 263 M | ||
|
NeoGenomics
NEO
|
837 M | $ 8.39 | 1.76 % | $ 1.07 B | ||
|
Neogen Corporation
NEOG
|
2.07 B | $ 9.45 | 3.73 % | $ 2.05 B | ||
|
Lantheus Holdings
LNTH
|
1.09 B | $ 78.83 | 0.41 % | $ 5.32 B | ||
|
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M | ||
|
Pacific Biosciences of California
PACB
|
5.35 M | $ 1.41 | 3.68 % | $ 423 M | ||
|
Co-Diagnostics
CODX
|
86 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
Medpace Holdings
MEDP
|
459 M | $ 458.61 | 1.1 % | $ 13.2 B | ||
|
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
-23.6 M | $ 1 220.43 | 1.77 % | $ 25.2 B | ||
|
Celcuity
CELC
|
116 M | $ 115.07 | 0.15 % | $ 4.54 B | ||
|
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | ||
|
Invitae Corporation
NVTA
|
102 M | - | - | $ 21.2 M | ||
|
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
706 M | $ 201.15 | 1.76 % | $ 19.8 B | ||
|
OPKO Health
OPK
|
1.37 B | $ 1.2 | 0.84 % | $ 833 M |